Home » Financial Reports 2018 » Notice of Annual and Special Meeting of Shareholders and Management Information Circular March 22, 2018
Most Recent Flipbooks
Annual Report 2018
2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.
Quarterly Report 2018 Q3
Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.
Quarterly Report Q2 2018
Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).
Quarterly Report Q1 2018